![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Kromek Group Plc | LSE:KMK | London | Ordinary Share | GB00BD7V5D43 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.05 | 5.80 | 6.30 | 6.05 | 6.05 | 6.05 | 109,127 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Miscellaneous Metal Ores,nec | 17.31M | -6.1M | -0.0102 | -5.93 | 36.31M |
Date | Subject | Author | Discuss |
---|---|---|---|
02/10/2021 18:24 | So what. Don’t seem like anyone bothered anymore. Your ramping is totally based on magazine snippets and YouTube blah blah. Investors are only interested in the share price rising. That’s not happening here! Until it does, give it a rest, mick33. | ![]() b00mb0y | |
02/10/2021 17:41 | Interesting FT article from a couple of weeks ago. Bioterror: the dangers of garage scientists manipulating DNA "These garage scientists might seem like a quirky new subculture but their rogue mindset is starting to generate consternation among those who specialise in managing biological threats in governments and international bodies. In 2018 the states that are signatories to the 1972 Biological Weapons Convention (BWC) identified gene editing, gene synthesis, gene drives and metabolic pathway engineering as research that qualifies as “dual use”, meaning it is as easy to deploy for harmful purposes as it is for good. Many of the parties are now worried that increased accessibility to such technologies could heighten accidental or deliberate misuse, including the development of biological weapons by rogue actors for mass or targeted attacks. | ![]() 33mick | |
02/10/2021 12:04 | 33 dot you know why | ![]() ali47fish | |
02/10/2021 11:06 | Kromek have had more coverage in Korea than here.... | ![]() 33mick | |
02/10/2021 10:49 | 세상/ Good video of the recent exhibition and some other lab areas. Who can read Korean? | ![]() 33mick | |
30/9/2021 13:50 | Oxford Nanopore soars 42% in conditional trading upon market debut today. | ![]() quepassa | |
30/9/2021 08:24 | Can someone get the nurse for retirementfund please. Looks like he’s out of bed. | ![]() b00mb0y | |
29/9/2021 22:57 | Momentum is returning here good to see the new order and the holdings RNS's. Would be nice to see a couple more orders and then will break out | ![]() retirementfund | |
29/9/2021 22:39 | Schrieber post on lse is bang on. | ![]() b00mb0y | |
29/9/2021 19:34 | Nice to see Newlands faith given their experience and background… | strategicinvestor2 | |
29/9/2021 17:10 | monique newland increases holding- is she a director? | ![]() ali47fish | |
28/9/2021 19:08 | It’s easy to forget why I bought into Kromek... the business taking a turn and due to make a profit (despite the large spend on IP). Plus the potential of the biological pathogen detector. To sell now as tempting as it is sometimes, as the share price is heading down with no obvious reasons or news - is as Warren Buffet would say ‘watching the scoreboard instead of the pitch’. | ![]() aqc888 | |
28/9/2021 09:25 | Well there's some appetite for Kromek this morning(yesterday pm) that's 3 x 100k & a delayed 250k from 8.01am. And plenty of other buys too. I'm holding out until the end of the year too, atleast. Surely has to be some positive update by then!?! | ![]() davethechef | |
28/9/2021 09:02 | It gave me some comfort to see Kromek have been patenting a lot in the last year. Mostly to do with the biological pathogen detector I presume. I’m a lot happier holding through these dips knowing that not only are they having their best financial year (not due to make a loss!) 80% of analysts forecast for the financial year already met, despite the spend on being 4th in the Intellectual Property 100 list. | ![]() aqc888 | |
28/9/2021 00:31 | Can anyone explain why its been implied in interviews and emails to investors that the Covid detector works fantastically well but they haven’t bothered to RNS what on earth is going on right now? Another 6 weeks minimum now of nothing. Is the thing finished but struggling to find buyers or is it still being tweaked? What is going on??? There unprofessionalism in regards to updating the market has caused a sell off. I’ve sold half myself these last few weeks and seems like many others have also. Maybe they want us to sell before they announce a huge order? Maybe there are no orders? Smoke and mirrors ? | ![]() ark87 | |
28/9/2021 00:31 | kmk have some great tech but the orders are usually small. The question I am starting to ask myself is when you factor in overheads are they making this great technology AT A LOSS?? I’ve done enough moaning here now will be my last post. I’ll be back to apologise if we ever do see serious upwards movement in the share price | ![]() ark87 | |
27/9/2021 22:14 | So Covid will probably morph into something like the common cold in the usual couple of years time frame - an H5N7 flu strain could be a real worry for the future and a vaccine for HIV could be a long way off. IMO GLA | simithy | |
27/9/2021 16:55 | as they cant buy during a closed period, any director buys inadvertently means nothing price sensitive happening for at least 6 weeks. Otherwise the purchase would be under scrutiny | ![]() fanramptastic mate | |
27/9/2021 16:32 | If it’s the start of a flurry of director buys it could have a positive effect. However I’d be a lot more at ease knowing they’ve invested more significant amounts. £50k buys would make me happier | ![]() aqc888 | |
27/9/2021 16:29 | A token gesture. What exactly are the regulations for insiders such as this director buying shares, when he must surely have access to detailed information on how the detectors progress is going? Better details than the market. | ![]() aqc888 | |
27/9/2021 16:29 | Directors buy- seems to show insiders confidence | strategicinvestor2 | |
27/9/2021 14:36 | £15k Directors buy. Seems like desperate attempt to stop the selling. | ![]() ark87 | |
27/9/2021 13:37 | Indeed. The Sciences and scientists tend to be highly specialised. Very, very rare that they are inter-disciplinary in my experience. CZT is one field and one specialisation - which is clearly the core activity and apparent strategy of Kromek. But a new product based on a fundamentally different branch of science - biotechnology- involving DNA-Sequencing is something completely different from CZT based applications. I'd personally like to understand better the resources and commitment - financial, technical and human - that the Company has to support a new development based on a biotech product and how many dedicated DNA-Sequencing specialists/ biotechnologists they have to develop and support this new activity. all imo.dyor. qp | ![]() quepassa |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions